HCPCS Code J0897: Injection, Denosumab, 1 mg

Learn HCPCS Code J0897: Injection, Denosumab, 1 mg for osteoporosis therapy, fracture management, bone density, and cancer-related skeletal events.

Use Code

## **What is an injection of denosumab (1 mg)?** An injection of denosumab (1 mg) is a targeted therapy used in the management of osteoporosis with current pathological fractures, particularly in patients experiencing an initial encounter for fracture due to age-related osteoporosis or other specified disorders of bone. This medication works by inhibiting osteoclast activity, helping to stabilize bone density and structure, increase bone mass, and reduce the likelihood of skeletal-related events. It is often prescribed when other available osteoporosis therapies are not effective or contraindicated. Denosumab is not indicated for treating cancer but for preventing skeletal complications associated with bone metastases or giant cell tumors. For instance, it plays a critical role in treating related osteoporosis with current pathological fracture left or current pathological fracture right, as well as conditions such as pathological fracture other site, fracture in neoplastic disease, and pathological fracture in neoplastic disorders associated with secondary malignant neoplasm or breast cancer. It is also indicated in patients with nonmetastatic prostate cancer, where prevention of skeletal complications is a medical necessity. When documenting treatment in the patient’s medical record, it is essential to identify the correct ICD-10-CM code to reflect whether the case involves an encounter for fracture age-related osteoporosis, subsequent encounter for fracture, or site subsequent encounter after healing has begun. Examples include fracture other site subsequent encounter, fracture left shoulder sequela, fracture left femur sequela, fracture left forearm sequela, and specific diagnoses like pathological fracture left ankle, pathological fracture left shoulder, pathological fracture left femur, or pathological fracture left forearm. Each reflects a different stage of care, from initial injury to sequela. Denosumab may also be required in patients with giant cell tumors of bone or complex disorders of bone density, which compromise skeletal integrity and heighten risk factors for injury. In cases such as right shoulder initial encounter or other trauma-related fractures, proper coding ensures both accurate reporting and demonstration of medical necessity for therapy. By addressing the mechanisms that underlie bone mass deterioration, denosumab reduces the incidence of current pathological fractures, provides stability, and supports recovery in patients with fragile skeletal health. Its integration into treatment plans ultimately reduces the burden of skeletal-related events and improves outcomes for individuals with complex fracture histories and a personal history of bone fragility.

## **HCPCS code J0897 documentation requirements** For J0897 (denosumab, 1 mg injection), documentation must show medical necessity and support correct billing. Records should include: - Specify osteoporosis, pathological fracture, or skeletal-related events (with correct ICD-10-CM codes such as initial, subsequent, or sequela encounters). - Note bone density findings, fracture history, or risk factors (e.g., breast cancer, nonmetastatic prostate cancer, or bone disorders). - Document why denosumab was chosen over other osteoporosis therapies. - Identify the exact fracture site and encounter type (e.g., right shoulder initial encounter, left femur sequela). - If applicable, include evidence for giant cell tumor, secondary neoplasm, or cancer-related fracture prevention.

## **J0897 billing requirements** Proper billing depends on confirming medical necessity, coding accuracy, and clinical justification, especially when linked to a diagnostic injection or therapeutic plan. Key requirements include: - Medical necessity must be clearly documented in the patient record. - Correct ICD-10-CM code that reflects the condition (e.g., osteoporosis, pathological fracture, breast cancer, skeletal-related events). - Clinical evidence, such as bone density results, fracture history, or risk factors for disorders of bone density. - Documentation of treatment rationale and why denosumab was chosen. - Proper notation of encounter type (initial, subsequent, or sequela). - If applicable, note use with a diagnostic injection or other therapeutic procedures. - Dosage and administration details must match the billing claim. - Provider’s signature and date to validate the record.

## **Other relevant codes** - A4216 – Sterile water/saline, used for reconstitution. - A4215 – Needle, sterile, any size, each.

Frequently asked questions

J0897 is often used as part of osteoporosis therapy to help strengthen bones and reduce the risk of fractures. It may be prescribed to Medicare beneficiaries who are at high risk for fracture, particularly in cases of osteoporosis without a current pathological fracture or in patients who have experienced a pathological fracture of the right shoulder, fracture of the right femur initially, or fracture of the right forearm initially. By decreasing bone resorption and improving bone density, this treatment helps prevent complications such as multiple myeloma–related bone damage or bone metastasis.

Yes. J0897 is appropriate for conditions such as bone metastasis from solid tumors or multiple myeloma, where there is a high risk for fracture and severe morbidity. It is often used alongside androgen deprivation therapy or adjuvant aromatase inhibitor therapy in cancer patients to protect bone density.

When billing, documentation should clearly state the type and site of fracture, such as fracture right shoulder initial, right femur initial encounter, right forearm initial encounter, or ankle and foot initial. For follow-up cases, terms like ankle and foot sequela or left ankle and foot may apply.